Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.
CONCLUSIONS: Eculizumab has the potential to be a key player in treatment of severe cases of COVID-19. Our results support eculizumab use as an off-label treatment of COVID-19, pending confirmation from the ongoing SOLID-C19 trial.
PMID: 32329881 [PubMed - as supplied by publisher]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Antiviral Therapy | Ceftriaxone | Coronavirus | COVID-19 | Drugs & Pharmacology | Emergency Medicine | Hydroxychloroquine | Intensive Care | International Medicine & Public Health | Kaletra | Lovenox | Norvir | Pneumonia | Respiratory Medicine | Rocephin | SARS